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ProstacycHn protects ischemic reperfused 
myocardium in the dog by inhibition of 
neutrophil activation 
Prostacycln (PGI,) and the stable PGI, analoguo SC39902 (6,s~epoxy&Wfluoro-1 la,15S- 
dehydroxyprosta-6,13E-dlen-l-ok acid, sodium salt) were studled In anesthetized open-chest 
dog8 subjected to 90 minutes of left circumflex coronary artery (LCCA) occlusion and 6 hours of 
reperfusion. PGlp (60 ng/kg/mln, infused into the left atrium) reduced infarct mass by 69% 
compared to control, but SC39902 (1.5 bg/kg/mln) failed to produce a slgnlficant reduction In 
Infarct size. Both PGI, and SC39962 reduced mean arterial blood pressure, heart rate, and 
rate-pressure product to the same extent. Regional myocardial blood flow measured wlth 
radioiabeiled tracer mlcroepheres dld not demonstrate an increase in regional blood flow to the 
Ischamk myocardium during the 90 minutes of LCCA occlusion in the PGI, and control treatment 
groups. Canine neutrophiis were isolated from whole blood and activated with opsonizad 
zymoaan. PGI, produced a concentration-dependent inhibition of nautrophll activation as 
measured by superoxide production In vitro, whereas SC39902 failed to effectlveiy inhlbit 
neutrophii activation. Neutrophll migration into Inflammatory skin lesions was effectively 
attenuated when dogs were pretreated with PO& (60 ng/kg/mln, Intravenously). Therefore, It is 
suggested that the cytoprotectiva effect of PGI, during myocardial ischemla and reperfuslon is 
related to an inhibition of neutrophll migration and the production of cytotoxic activated oxygen 
species. (AN HEART J 1967;113: 129.) 
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Prostacyclin (epoprostenol, PGI,) is the major active 
arachidonic acid metabolite produced by vascular 
endothelium.1*2 It is the most potent endogenous 
inhibitor of platelet aggregation yet described,’ and 
is a potent systemic vasodilato~ and coronary artery 
vasodilator.’ Proetacyclin has been demonstrated to 
be protective in a number of experimental models of 
myocardial ischemia.54 Lefer et aLg demonstrated 
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the usefulness of PGI, for the treatment of acute 
myocardial ischemia. This was based on the ability 
of PGI, to inhibit platelet aggregation and favorably 
alter myocardial oxygen supply and demand by 
increasing coronary artery blood flow and reducing 
systemic blood pressure, respectively. Melin and 
BeckerlO demonstrated that PGI, protects in the 
absence of an increase in collateral blood flow to the 
ischemic myocardium. 
Recent studieF3 have provided substantial evi- 
dence to demonstrate that polymorphonuclear leu- 
kocyte (neutrophil) infiltration during an evolving 
myocardial infarct contributes to irreversible myo- 
cardial tissue injury. Since prostacyclin inhibits in 
vitro production of cytotoxic oxygen-free radicals 
and release of degradative lysosomal enxymes,14-16 we 
hypothesize that the cytoprotective effect of PGI, in 
canine regional myocardial ischemia and reperfusion 
is at least partly due to inhibition of neutrophil 
activation. 
The purpose of this investigation was to deter- 
mine the effectiveness of PGIz and the chemically 
stable mono-fluorinated PGI, analogue (SC39992; 
6,9cr-epoxy,5S-fluoro-llq 15S-dehydroxy-prosta- 
6,13E-dien-1-oic acid, sodium salt) for reducing the 
extent of irreversibly injured myocardial tissue that 
results after 90 minutes of regional ischemia and 6 
hours of reperfusion. We report on the effects of 
PGI, and SC39962 on canine neutrophil activation 
by the particulate phagocytic stimulus, opsonixed 
zymosan, as measured by superoxide anion produc- 
tion in vitro. Additionally, we report that PGI, 
inhibits neutrophil migration in vivo into inflamma- 
tory skin sites at the same dose that reduces myocar- 
dial ischemia-reperfusion injury. 
METHODS 
Details of the methods have been published previous- 
ly.12v17 Briefly, adult male mongrel dogs (12 to 17 kg) were 
anesthetized with Dial-urethane (0.6 ml/kg) and venti- 
lated with room air. The proximal left circumflex coronary 
artery (LCCA) was isolated and instrumented for contin- 
uous blood flow measurement with an electromagnetic 
flow probe. Heart rate, arterial blood pressure, LCCA 
blood flow, and ECG were continuously recorded. The 
three experimental groups in the study were: (1) Control 
(vehicle) (n = 16), 50 mM Tris-HCl, pH 9.4 at 4’ C in 
0.9% saline; continuous infusion (0.5 ml/mm) into the left 
atrium beginning 30 minutes before coronary artery occlu- 
sion, continuing during the 90 minutes of regional ische- 
mia, and continuing during the first 2 hours of reperfu- 
sion. (2) Prostacyclin (n = 14), 50 ng/kg/min in the same 
vehicle, over the same time course as control. (3) SC39902 
(G.D. Searle & Co.) (n = lo), 1.5 &kg/min (same vehicle 
and time course). 
Regional myocardial ischemia was produced by occlud- 
ing the LCCA for 90 minutes and then reperfusing 
through a critical stenosis1E for 6 hours. After 6 hours the 
infarct mass was aasesed with the ex vivo dual perfusion 
technique previously described,‘* in which the LCCA is 
perfused with 1.5% triphenyltetrazolium chloride in 50 
mM potassium phosphate buffer (pH 7.4 at 37’ C) and the 
remainder of the coronaries are perfused with 0.25% 
Evan’s blue dye. The hearts were then cut into five or six 1 
cm thick transverse sections. Infarct size was then deter- 
mined planimetrically. 
Regional myocardial blood flow (RMBF). Radioactive 
microspheres (15 Nrn) (New England Nuclear, North 
Biller& Mass.) labelled with one of the following five 
isotopes-Wr, 141Ce, sSSr, lwRu, *SC-were used to assess 
regional myocardial blood Aow,‘~ essentially as detailed 
previously.” The times of microsphere injection were as 
follows: baseline (before drug or vehicle infusion), 25 
minutes after drug or vehicle infusion, 10 minutes after 
LCCA occlusion, and 30 minutes after LCCA occlusion. 
Tissue samples weighing 0.5 to 1.0 gm were dissected 
from sections of the hearts after staining, from subepicar- 
dium, midmyocardium, and subendocardium from the 
LCCA perfusion region (which was rendered ischemic), 
and from the normally perfused nonischemic region. 
Three sections from each heart were used so that blood 
flows to each region represent the average of three samples 
for each experiment. 
Histology. A midventricular transmural section of the 
area of the left ventricle supplied by the LCCA was 
examined by light microcopy in 21 hearts, seven from each 
of the three treatment groups (control, PG12, SC39902). 
Pa&in-embedded tissue blocks were sectioned at 5 
thickness and were stained with hematoxylin and eosin. 
The presence of necrosis was verified and the degree of 
hemorrhage was assessed by a pathologist (GDA) unaware 
of the experimental treatment groups. 
Neutrophil preparation. Canine neutrophils were isolat- 
ed from venous blood obtained from untreated dogs and 
were separated by Hi&opaque (Sigma Chemical Co., St. 
Louis, MO.) gradient centrifugation followed by red blood 
cell lysis with a buffered ammonium chloride solution (150 
mM [NH,] *C12; 10 mM NaHCO,; 1mM EDTA; pH 7.2). 
Cell viability was greater than 90% as determined by 
trypan blue exclusion. Cell preparations consisted of 
greater than 95% neutrophils.. Superoxide (0,; )produc- 
tion was measured by a modification of the method of 
Babior et alp as described by Fantone and Kinnes.” 
Neutrophils (5 X 108 cells/ml) were incubated at 37O C 
in the presence of 0.1 mM ferricytochrome C in Hanks’ 
balanced salt solution (HBSS) with 1 mg/ml glucose. The 
rate of superoxide production was determined as the 
superoxide diamutase (SOD) inhibitable (SOD 50 &ml in 
reference tubes) reduction of ferricytochrome C to ferro- 
cytochrome C with the use of an extinction coefficient of 
21.1 mM-’ cm-’ at 550 mn. After an initial 3- minute 
incubation at 37O C, Cyto&Iasin B (5 fig/ml) wae added 
and 2 minutes later, opsonized zymm (OZ) (10% of 
final volume) was added to the neutrophils. OZ was 
prepared by incubation of normal dog serum with zymo- 
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Table I. Hemodynamic measurements 
Control Prostacyclin 
(n = 16) (n = 14) 
SC39902 
(n = 10) 








Rate-pressure product (mm 





145 + 6 
148 k 6 
13s * 5 
151 + 8 
11Sk 4 
11s * 4 
93 f 4 
91 f 4 
21.6 + 1.4 
22.7 f 1.6 
16.7 + 1.0 
17.4 Yk 1.8 
124 IL 5t 
11s * 5t 
124 + 5 
148 f 8 
115 + 5 
88 z?z 5t 
78 k 4* 
93 + 5 
18.1 + 1.2 
14.1 k o.st 
13.5 + 1.0 
18.5 r 1.4 
138 f 8 
130 + s* 
13s + 5 
180 f 13 
119 + 6 
101 + 5t 
so f 3 
102 i 5 
20.1 k 1.4 
16.2 +- 1.2t 
16.1 + 1.0 
23.6 + 2.0 
All values expressed as mean + standard error. 
Baseline = before drug; Drug = 30 minutes after vehicle or drug infusion; Occlusion = 30 minutes after LCCA occlusion; Reperfusion = 6 hours after LCCA 
reperfwion. 
*p < 0.05, tp < 0.01, compared to control at same time point. 
san A (Sigma; 10 mg/ml) for 30 minutes at 37’ C and then 
by washing the zymosan twice with sterile normal saline. 
The OZ was then resuspended in normal saline to 10 
mg/ml. Pro&gland& when present, were serially dilut- 
ed immediately before use in HBSS (4’ C) and were added 
at the’ same time as the cells. 
Evaluation of neutrophil migration in vivo. Seven dogs 
were anesthetized with Dial-urethane and (randomized 
into one of two treatment groups: (1) Prostacyclin, 50 
ni/kg/min in vehicle (50 mM Tris HCI buffer (pH 9.4 at 4O 
C) in 0.9% saline) by intravenous infusion 0.5 ml/min; or 
(2) Control (vehicle). The chest and back of each dog was 
carefully shaved and zymosan-activated dog plasma 
(ZAP) (0.2 ml) was injected intradermally at random sites 
30 minutes after the respective intravenous treatment had 
begun. ZAP was prepared by incubating normal dog 
plasma with zymosan A (10 mg/ml) for 30 minutes at 37” 
C and then removing the zymosan by centrifugation. 
Biopsies (100 to 300 mg each) were taken at 0,0.5,1.0, and 
2.0 hours after ZAP injection. The neutrophil-specific 
enzyme, myeloperoxidase*l was extracted and measured 
spectrophotometrically as detailed by Bradley et aL2* The 
myelo$roxidase content of tissue has been shown to be a 
good marker of akin neutrophil content.*‘tz2 
Statistical analyses. Hemodynamic data (heart rate, 
mean arterial pressure rate-pressure product, LCCA blood 
flow) and infarct sizes were analyzed with a one-way 
analysis of variance (ANOVA) at each time point where 
there were,three groups (control, PGI,, and SC39902). The 
&ups of data that were found to be significantly different 
from the ANOVA were analyzed further with Dunnett’s 
test for multiple comparisons to control.23 p values less 
than 0.05 were considered significant. Regional myocardi- 
al blood flows (RMBFs) were analyzed with unpaired 
Student’s t tests for each comparison between the two 
treatment groups. Paired Student’s t tests were used to 
test for differences with time in the RMBF studies?’ A 
Bonferroni a-error protection was used if any of these 
differences were found to be significant. In vitro superox- 
ide production was analyzed by unpaired Student’s t test 
for each concentration of PGI, or SC39902 compared to 
the superoxide production in the absence of either PGI, or 
SC39902. Myeloperoxidase content of tissue samples were 
compared by Student’s t test. 
RESULTS 
Thirty-four dogs were assigned randomly to one 
of the three treatment groups (control, PG12, or 
SC39902) for initial assessment of drug effect on 
resulting myocardial infarct size. Three dogs, one 
from each of the three treatment groups, were 
eliminated due to ventricular fibrillation during 
reperfusion which was not converted with fewer 
than four DC countershocks. Fourteen more dogs 
were randomized into one of two treatment groups 
(control or PGI,) for assessment of treatment effects 
on changes in RMBF. Of these 14 dogs, three control 
dogs and one PGI,-treated dog were eliminated from 
the study due to ventricular fibrillation. Two more 
dogs (one control, one PGIJ were eliminated from 
the study due to technical problems with micro- 
sphere injection and reference blood sample with- 
drawals. 
Hemodynamlc effects of PGll and SC3WO2. The 
doses of PGI, (50 ng/kg/min) and SC39902 (1.5 
&kg/min) were chosen on the basis of their ability 
to produce a similar decrease in blood pressure. 
Pro&a&in infusion resulted in a 23% reduction 
(-27 mm Hg) in mean arterial blood pressure 
(MAP) (Table I) after 30 minutes of infusion, from 
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Fig. 1. Left circumflex coronary artery (LCCA) blood flow 
at regular intervals during the experiments. Drug or vehicle 
infusion was begun after recording 0 hour flows and was 
continued until 2 hours after reperfusion (4 hours). The 
LCCA was occluded for 90 minutes, beginning after 30 
minutes of drug or vehicle infusion. There were no differences 
among treatment groups at any time point (ANOVA). 
115 + 5 to 88 f 5 mm Hg (n = 14). Similarly, infu- 
sion of SC39902 resulted in a reduction in MAP 
from 119 + 6 to 101 rt 5 mm Hg (n = 10). Occlusion 
of the LCCA typically results in a decline in MAP, as 
demonstratd in Table I comparing control before 
occlusion (119 + 4 mm Hg) to control at 30 minutes 
of regional myocardial ischemia (93 f 4 mm Hg). 
MAP was comparable after LCCA occlusion among 
all three treatment groups throughout the 6-hour 
reperfusion period. 
Baseline heart rates (HR) (Table I) were slower 
in the PGIz-treated group (p < 0.06); however, after 
30 minutes of PGI, or SC39902 infusion, both PGI, 
and SC39902 groups had significantly slower heart 
rates compared to control (both p < 0.05). Heart 
rates were comparable among groups during the 
90-minute ischemic period and throughout the 6- 
hour reperfusion period. 
Rate-pressure product (RPP) (systolic blood 
pressure x heart rate/lOOO) is used as an index of 
myocardial oxygen consumption.25 RPP was moni- 
tored throughout the experiments to determine 
whether changes in oxygen demand due tc treat- 
ment could be responsible for any protective effect 
on the resulting myocardial infarct size. Baseline 
mean values for RPP did not difk’er among the three 
treatment groups (Table I) (Control: 21.6 + 1.4 mm 
Hg/min/1000; PGI,: 18.1 + 1.2 mm Hg/min/lW, 
SC39902: 20.1 + 1.4 mm Hg/min/lOOO). However, 
after 30 minutes of infusion of PGI, or SC39902, 
rate-pressure product was significantly reduced in 
both PGI, and SC39902 treatment groups compared 
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to control @ < 0.01). Upon LCCA occlusion, this 
index was similar among groups and remained so 
throughout the g-hour reperfusion period. 
Mean LCCA blood flows were comparable before 
treatment (Fig. 1). After 30 minutes of infusion of 
PGI, or SC39902, LCCA coronary blood flows were 
similar when compared to the vehicle control group 
(control = 27 & 3 ml/min, n = 16; PGI, = 19 + 2 
ml/min, n = 14; SC39902 = 22 + 4 ml/min, n = 10; 
PGI, both p > 0.05 compared to control). After 90 
minutes of complete LCCA occlusion, blood flow 
was resumed slowly over 15 minutes. All mean 
LCCA blood flows were comparable among groups 
at every time point observed subsequent to reperfu- 
sion. 
Effects of PGlz and SC39902 on infarct size. The 
effects of PGI, and SC39902 on resulting myocardial 
injury due to ischemia and reperfusion are depicted 
in Fig. 2. The ratios of the amount of left ventricle 
rendered ischemic (AREA AT RISK [AR]) to the 
total left ventricle (LV) were equivalent among the 
three treatment groups (control: n = 13, AR/ 
LV = 45.5 + 1.7%) PGI,: n = 12, AR/LV = 40.3 f 
2.4%; SC39902: n = 10, AR/LV = 48.9 + 2.1% ; 
p >0.05 by ANOVA). Infarct size was reduced signif- 
icantly with PGI, treatment (p < 0.001 by ANOVA 
and Dunnett’s, control vs PGIJ when expressed as a 
percentage of LV or as a percentage of the area at 
risk. On the other hand, SC39902 demonstrated a 
hemodynamic profile (HR, MAP, RPP, LCCA blood 
flow) similar to that with PGI, but failed to signifi- 
cantly alter the size of the myocardial infarct that 
evolved after 90 minutes of regional ischemia and 6 
hours of reperfusion. Infarcts expressed as a per- 
centage of the area of myocardium at risk were as 
follows: control: n = 13, 47.4 + 4.7%; PGI,: n = 12, 
19.2 + 2.0%; SC39902: n = 10, 36.5 + 5.5%; 
(p < 0.001 Dunnett’s, control compared to PGI,). 
Regional myocardial blood flows were determined 
at four time points during the experiments (Fig. 3). 
The purpose of measuring RMBF is to determine 
whether the protective effect of PGI, on the evolving 
mass of myocardial infarct is due to alteration of 
regional blood flow distribution. LCCA occlusion 
resulted in a significant decline in myocardial blood 
flow in all three myocardial regions (subepicardial, 
midmyocardial, and subendocardial) and to a simi- 
lar extent in both control and the PGI, treatment 
groups. Endocardial blood flow was reduced by 91% 
and 93 % in control and pro&a&in treated groups, 
respectively; midmyocardial flow declined by 84% 
(control) and 91% (PGI,); and epicardial flows 
declined by 67 % (control) and 85% (PGIJ. Blood 















Fig. 2. Myocardial infarct size was measured after 6 hours 
of repeifusion. Mean infarct mass is expressed as a percentage 
of the area of the myocardium at risk of infarction, depicted as 
individual points for each experiment along with the mean 2 
standard error of the mean for each treatment group. PGI, 
treated dogs developed a significantly smaller infarct com- 
pared to controls (**p < 0.01, ANOVA, Dunnett’s). 
during LCCA occlusion in the ischemic perfusion 
bed when early (10 minutes after occlusion) and late 
occlusion (30 minutes after occlusion) flows were 
compared (paired t test). Therefore, there was no 
significant increase in collateral flow that could 
account for the protective effect of PGI, on the 
evolving infarct mass. EndocardiaUepicardial blood 
flow ratios were calculated to determine if the blood 
was being redistributed within the myocardium. 
Endocardial/epicardial flow ratios remained un- 
changed with treatment (control pretreatment 
1.38 * 0.07 .ml/min/gm, after vehicle 1.38 + 0.08 
ml/min/gm; PGI, pretreatment 1.17 + 0.03 ml/min/ 
gm, after PGI, 1.08 k 0.09 ml/min/gm) in the region 
of the myocardium perfused by the LCCA. The 
endocardial/epicardial ratios during occlusion with- 
in the ischemic area were 0.4 + 0.11 for the PGI, 
group and 0.15 t- 0.40 for the control group 
0, > 0.05). This again confkns that the protective 
effect of PGI, on infarct size is independent of blood 
flow redistribution. Blood flows in the area of the 
heart not rendered ischemic are depicted on the 
right side of Fig. 3. As is evident from the figure, 
there were no significant differences in blood flows 
in this region with time (paired t test) or between 
groups (control, PGIJ at any time tested (unpaired t 
test). EndocardiaVepicardial flow ratios in the non- 
ischemic regions were similar to endocardial/epicar- 
dial ratios obtained in the region perfused by the 
LCCA. 
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Fig. 3. Regional myocardial biood flow to the region of the 
heart that is rendered ischemic is depicted on the left halfof 
the figure. On the right is the nonischemic region. Subendo- 
cardial (ENDO) blood flow is depicted in the top two panels, 
midmyocardial (MID) flow is shown in the middle two panels, 
and subepicardial (EPI) flow is illustrated in the bottom two 
panels. Baseline [Bj blood flow represents before PG12 or 
vehicle infusion. RX represents 25 minutes after PG& or 
vehicle infusion. 01 and 02 represent 10 and 80 minutes, 
respectively, after LCCA occlusion. There were no significant 
differences between groups (Student’s t test) in any region or 
at any time point (Control -filled circles; PGIz = filled 
triangles). 
Histology. Representative transmural sections 
from each of 21 hearts were used to assess relative 
degree of ischemic injury by light microscopy. Tis- 
sue samples were prepared for histologic examina- 
tion such that regions from the central infarct area, 
the border region between normal tissue and neerot- 
ic tissue, and the normal tissue were analyzed. No 
&nificant differences were observed among the 
three treatment groups (control, PGI,, SC39%2) 
with respect to the appearance of the-necrotic tissue 
in the central infarct area. No differences among 
treatment groups were discernible with respect to 
the extent of hemorrhage in the infarct area or 
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Flg. 4. Inhibition of superoxide generation by PGI, but not 
by SC39902. Canine neutrophils were activated with opso- 
nized zymosan. PGIZ produced a concentration-dependent 
inhibition of 02: generation while SC39902 weakly inhibited 
only at 10e6M. Each symbol represents the mean t S.E.M. of 
three determinations except .that n = 6 for 0 PGIl or 
SC39902. PGI, or SC39902 were serially diluted in cold 
Hank’s buffer immediately before addition to the tubes. 
**p < 0.001 compared to 0,; in the absence of PGI, or 
SC39902. 
border regions. Gross inspection of histologic sec- 
tions revealed no dis~rnible differences in relative 
neutrophii content in infarcted tkisue or border 
regions. 
Frequency or uentricular flbrWt#on. The develop- 
ment of spontaneous ventricuiar fibrillation (YF) 
was monitored in this study to determine whether 
PGIe or SC39902 may a&t the frequency of VP. 
Previous reporta suggest that PGI, and ,PGI, ana- 
logue8may be either antiarrhythmic or arrhythmog- 
enic, depending on the dose of drug ,J.NKxL~,~’ The 
overall incidence of VF was 7 of 46 dogs in the study 
with control frequency of 4 of 19, for PGI, it was 2 of 
18 dogs, and for SC39902 it wan 1 of 11 dogs (chi 
s&are = 1.166, p > 0.05). Therefore was no dif.@r- 
ence in the relative frequency of observed in this 
study. 
In vitro ~upewxtd0 production by oar~lni niuw. 
Ctiine ~eutzoph& ‘were stimuhs&ed with 02 and 
superoxide Oa- generation was ma&ored qe@ro- 
photometriklly (at 550 mn) by the superoxide 
dismutase inhibitable reduction .of ferriqW&rome 
C. Fig. 4 dernonstrafea that proetaoyohn prodti a 
concentration-dependent inhibition of neutrophii 
activation. The rate of superoxide production in the 
absence of PGI, or SC39902 ~88 15.23 I: 0.22 
0 0.5 1.0 2.0 
time (hours) after ZAP injection 
Fig. 5. Inhibition of neutrophil migration into inflammatory 
skin lesions. The number of individual biopsies is in pure&e- 
ses. Vertical lines represent the standard error of the mean 
(**p < 0.01, Student’s t test). The symbols represent the 
mean of four vehicle treated and 3 PGIz treated dogs. PGI, 
dose was 50 ng/kg/min intravenously. 
nmolea 0,;/5 x lo6 cells/l0 minutes. PGI, at a 
concentration of lo-‘M inhibited 0,: production by 
27 % compared to control (no PG). At a PGI, concen- 
tration of lo-‘M, superoxide production was inhibi- 
ted by 55% compared to control. In contrast, 
SC39902 did not ahow a concentration-dependent in- 
hibition of superoxide production. Moreover, 
SC39902 at a concentration of 10-W was the only 
concentration that was found to be significanfly dif- 
ferent from control. At this concentration, SC39902 
inhibition wa+3 only 11% compared to control. 
Neutrophil migration into dermal inflammatory 
leaions. Fig. 5 shows that prostacyclin at 50 ng/kg/min 
effectively inhibits neutrophil migration into skin 
lesions induced by activated complement fragments 
(primarily C5a de&g). The myeloperoxidase content 
at the time of zymosan-activated plasma (ZAP) injec- 
tion was 0.41 u 0.08 U/gm in the vehicle treated group 
and 0.M -t 0.24 U/gm in the PGI, treated group 
(p > 0.05). The myeloperoxidase content of skin lesions 
W8S ly less at 0.5, 1.0 and 2.0 hours after 
ZAP injection (all p < 0.01 compared to control). 
Furthermore, neutrophilic infiltration in the PGIz 
treated dogs was only 36.3% of the control value at the 2 
hour time point (14.68 +: 3.01 Ufgm vs 5.33 rt 0.65 
Wm). 
VOlUlMl 113 
Number 1 Prostacyclin and myocardial &hernia 135 
DISCUSSION 
A number of investigators have attempted to define 
the relevant mechanism for the myocardial protection 
by prostacyclin in the setting of experimental myocardi- 
al ischemia.6-10~28* 2g The reduction of arterial blood 
pressure by PGIz would at least theoretically reduce 
myocardial ischemia by reducing afterload and thus 
myocardial oxygen demand.30*31 In the present study; 
myocardial oxygen consumption as estimated by the 
rate-pressure productz5 was reduced to the same extent 
by PG12 and SC39902 (Table I). Prostacyclin resulted 
in a 59% reduction in infarct size with respect to the 
area at risk compared to controls, whereas SC39902 
failed to reduce infarct size (Fig. 2). The relevant 
mechanism of protection by PGI, is therefore not due to 
a reduction in myocardial oxygen demand. 
Jugdutt et al.6 demonstrated that PG4 by virtue of 
its vasodilatory properties, increased collateral blood 
flow to the ischemic myocardium in closed-chest con- 
scious dogs subjected to permanent coronary artery 
occlusion. Indeed, in the aforementioned study, protec- 
tion of the ischemic myocardium after permanent 
coronary artery occlusion is probably dependent upon 
the ability of PG12 to increase collateral blood flow, 
since PGE, and PG12 reduced infarct size while PGE, 
did not. Prostaglandins E, and I2 increased collateral 
blood flow in that study but PGE2 did not, while all 
three prostaglandins produced a similar reduction in 
blood pressure. In another study, Melin and BeckerlO 
demonstrated that even in the absence of increased 
collateral blood flow to the ischemic myocardium, PGI, 
treatment resulted in a reduction in myocardial necro- 
sis. We report that PGI, reduced infarct mass without 
increasing collateral blood flow to the ischemic myocar- 
dium during 90 minutes of regional ischemia. LCCA 
blood flow during reperfusion was similar among the 
three treatment groups (control, PG12, X39902; Fig. 
l), suggesting that the mechanism of protection was 
independent of changes in blood flow to the previously 
ischemic myocardium and was not related to the “no- 
reflow” phenomenon.32 
We hereby offer an alternative explanation for the 
cytoprotective effect of PG12 in ischemic myocardium in 
vivo. Prostacyclin can inhibit human neutrophil stimu- 
lation by formylmethionyl-leucyl-phenylalanine (f- 
Met-Leu-Phe) and zymosan activated serum (comple- 
ment activation products) as determined by superoxide 
production and lysosomal enzyme release in vitro.L’L6 In 
addition, prostaglandms of the E series inhibit neutro- 
phi1 chemotaxis, superoxide production, and degranula- 
tion in a variety of species, presumably through an 
increase in neutrophil intracellular concentration of 
cyclic adenosine monophosphate (AMP).16 We report in 
this study that PG12 can effectively inhibit canine 
neutrophil activation in vitro as measured by superox- 
ide-specific reduction of ferricytochrome C. The PGI, 
analogue SC39902 manifests hemodynamic effects sim- 
ilar to those of PGI, in vivo (i.e., reduces blood 
pressure) and also inhibits platelet aggregation in vitro 
(unpublished observations). A recent report33 demon- 
strated that SC39902 is an effective inhibitor of platelet 
activation in vivo as measured by the ability to prevent 
adenosine diphosphate (ADP)-induced thrombocytope- 
nia in rats. Despite these similarities to PG12, the 
analogue SC39902 failed to produce effective inhibition 
of canine neutrophil activation in vitro when stimulated 
with OZ. Furthermore, SC39902 does not protect the 
ischemic-reperfused myocardium with respect to ulti- 
mate infarct size. We propose, therefore, that the 
relevant mechanism for PG12 protection in our experi- 
mental model is via the inhibition of neutrophil activa- 
tion. 
The concentration of PG12 that produces 50% inhibi- 
tion of neutrophil O,- production is very similar to the 
30 PM of PGI, for 50% inhibition reported by Fantone 
and Kinnes.14 The concentrations of PGI, achieved in 
vivo with an infusion rate of 50 ng/kg/min would be 
expected to approach the concentration range of 10e7 in 
vivo. Furthermore, inhibition of neutrophil migration in 
vivo by PGI, (50 ng/kg/min) was demonstrated and is 
likely to be the relevant mechanism of protection of the 
ischemic reperfused myocardium. 
The proinflammatory role of the neutrophil during 
myocardial ischemia and reperfusion injury has been 
demonstrated.” Hill and Ward34 in 1971 demonstrated 
that complement is activated via the alternative path- 
way during myocardial ischemia. Maroko et a1.35 
depleted dogs of complement component 3 (C3) with 
cobra venom factor. Complement depletion resulted in 
reduced tissue damage and reduced neutrophil infiltra- 
tion into the ischemic myocardium. Pinckard et a1.36 
extended these observations to the baboon, and demon- 
strated complement localization within the ischemic 
myocardium by direct immunofluorescence methods. 
Neutrophils, when activated by complement fragments, 
produce oxygen-derived free radicals and release degra- 
dative lysosomal enzymes, both of which are capable of 
mediating tissue destruction. 
Using another approach, Romson et a1.12 demon- 
strated a 44% reduction in the mass of myocardial 
infarct that evolved when dogs were made neutropenic 
before the induction of regional myocardial &hernia. In 
a related study, Romson et al.” demonstrated that the 
protective effect of ibuprofen (a nonsteroidal anti- 
inIlammatory agent) upon the ischemic/reperfused 
myocardium was correlated with the ability of the drug 
136 Simpson et al. 
to inhibit the infiltration of neutrophils into the ischem- 
ic myocardium. Kuehl et a1.37 demonstrated that PGI, 
inhibits neutrophil lipoxygenase activity. Neutrophil 
lipoxygenase products provide an important proinflam- 
matory amplification signal. Leukotriene B,, produced 
by neutrophils, is a potent chemoattractant for neutro- 
phils, macrophages, and blood monocytes. Inhibition of 
lipoxygenase by PGIz would therefore result in a 
reduction in phagocytic cell infiltration and thus reduce 
cellular necrosis. 
In summary, we report the effectiveness of PGI, for 
reducing myocardial infarct mass in the dog with 
temporary regional myocardial ischemia and reperfu- 
sion. The PGI, analogue SC39902 produced a similar 
reduction in arterial blood pressure and heart rate but 
failed to reduce infarct mass. In vitro canine neutrophil 
activation was inhibited in a concentration-dependent 
manner by PGII, whereas SC39902 failed to effectively 
inhibit neutrophil activation over the same concentra- 
tion range. The data on neutrophil migration into 
inflammatory skin lesions demonstrate that neutrophil 
function is affected in vivo at the same dose of PGI, that 
reduces myocardial ischemic reperfusion injury. These 
data suggest that the cytoprotective effect of PGI, in 
this experimental model of myocardial infarction is due 
to inhibition of neutrophil activation. 
The studies described in this report may have rele- 
vance with respect to the clinical management of 
patients who are evolving an acute myocardial infarc- 
tion and who become candidates for thrombolytic 
therapy with streptokinase or perhaps tissue plasmino- 
gen activator. There are sufficient data to suggest that 
PGI, is capable of preventing platelet aggregation2 and 
that the prostanoid may be of value as an adjunct to 
thrombolytic therapy, whereby it may serve to prevent 
reocclusion of the successfully recanalized coronary 
artery?* The data presented in this report might give 
added importance for the concomitant use of PGI, 
along with thrombolytic therapy as an approach for the 
prevention of that component of myocardial injury 
associated with reperfusion of the ischemic heart. Fur- 
thermore, our data with respect to the cytoprotective 
effect of PGI*, while in agreement with that of previous 
investigators,5-‘0 provide an explanation for the mecha- 
nism by which PGIz elicits its beneficial action through 
an inhibition of neutrophil function. 
We wish to acknowledge the assistance of Dr. Marshal Shlafer with 
the neutrophil superoxide assays and that of Dr. Richard A. Gerren 
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assistance of Kim Kanitz. and Laura Sell and the technical assistance 
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Hemodynamic effects of BTS 49465, a new 
long-a&kg systemic vasoditator drug, in 
patients with severe congestive heart failure 
The hemodynamlc effect8 of BTS 49465, a new oral, direct-acting systemk varodilator drug, 
wore inve8tfgated in 10 patlantr wlth severe chronic congestive heart failure. One to 2 hours 
aftar the admhlstratlon of 1.6 mg/kg orally, BTS 49466 produced dgnlficant increases in 
cardiac Max, stroke vokrme index, and stroke work index (26%, 27%, and 23%, respectively, 
p < 0.01 to 0.001) and marked decreases In laft ventricular tllllng pressure (-12.6 mm Hg, 44%), 
mean puknonary artery pressure (-13.2 mm Hg, 31%), and mean right atrlal pressure (-7.7 mm 
Hg, 83%), a5 p < 0.001, wlthout slgnlflcant changer ln heart rata. There hamodynamk responses 
were accompanied by notable declines In systamlc vascular resistance (-26%, p < 0.001) and 
pulmonary artarlolar redstance (-24%, p < 0.06). These affacts persisted throughout the 24hour 
period of obaarvation. The decline In left ventricular fllllng pressure In our patlants ranged In 
magnltuda from 8 to 21 mm Hg, and varlad linearly and directly with pratrastmant values for left 
vantrkular fllllng prassura (r = 0.69). The dacraasa In ryrtamlc varcutar rarlrtance ranged In 
magnitude from 3% to 40% and varlad linearly and directly with pretreatment values for systemic 
varcular raslrtance (f = 0.65). These data Indlcata that BTS 49466, a new oral, direct-acting 
vasodllator agent, exerts balanced cardloclrculatory affects in patlants with severe chronic heart 
failure, which may ba surtainad with once-dally oral admlnistratlon. (AM HEART J 1987;113:137.) 
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